Buy Tesamorelin + Ipamorelin Blend, 10-15 mg

Shop by goal

Popular compounds

BPC-157

Research resources

Compare pack sizes

Tap a pack to select it in the purchase panel above

Lab-direct quality — sealed 10-vial packs

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack in the strength your research needs.

Scientific Research Context

What the published literature on the components of Tesamorelin + Ipamorelin Blend examines. These are findings about each compound in the studies cited, not claims about the blend or the supplied material.

Published tesamorelin trial: HIV-associated abdominal adiposity (the approved medicine, not this material)

In a 26-week randomised, placebo-controlled trial of 412 people with HIV and abdominal fat accumulation, tesamorelin lowered visceral adipose tissue by 15.2% (placebo +5.0%), raised IGF-I by 81% (placebo -5%) and improved triglycerides and the cholesterol to HDL ratio. More people on tesamorelin withdrew for adverse events. [human, tesamorelin alone]

Published tesamorelin trial: HIV and hepatic fat (the approved medicine, not this material)

In 61 people with HIV and fatty liver disease, tesamorelin over 12 months reduced hepatic fat fraction by 4.1 percentage points more than placebo (a 37% relative reduction), with more administration-site complaints in the tesamorelin group. [human, tesamorelin alone]

Ipamorelin: selective GH release

In rat pituitary cells, anaesthetised rats and conscious swine ipamorelin released growth hormone with a potency and efficacy comparable to GHRP-6, without the rise in ACTH and cortisol seen with GHRP-6 and GHRP-2, even at more than 200 times its GH-releasing ED50. [animal and in vitro]

Two different receptors

Antagonist profiling placed ipamorelin's action at a GHRP-like receptor and not the GHRH receptor that tesamorelin targets, which is the reason the pair is of interest to study together. [in vitro and animal]

Overview

In short: A research blend of tesamorelin and ipamorelin in three strengths (5 + 5, 10 + 4 and 10 + 5 mg per vial): a GHRH analogue and a selective ghrelin-receptor agonist in one vial.

Key research facts

Two growth-hormone-axis research peptides in one vial, in three strengths

Strengths: 5 + 5 mg, 10 + 4 mg and 10 + 5 mg (10, 14 and 15 mg per vial)

Tesamorelin: GHRH(1-44) analogue with a trans-3-hexenoyl N-terminal modification

Ipamorelin: pentapeptide characterised as a selective growth hormone secretagogue

The ratio differs by strength and is shown beside each printed vial code

These points summarise lab themes, not human outcomes.

Tesamorelin is the better documented half of the pair. It is the 44-residue growth-hormone-releasing hormone sequence with a trans-3-hexenoyl group on the N-terminus, and a 2007 randomised trial in 412 people with HIV and abdominal fat accumulation, followed for 26 weeks, reported a 15.2% fall in visceral adipose tissue against a 5.0% rise on placebo and an 81% rise in IGF-I against a 5% fall. A 2019 trial in 61 people with HIV and fatty liver reported a 4.1-point absolute reduction in hepatic fat fraction at 12 months. Both are studies of tesamorelin alone, in specific patient groups, and neither is evidence about the supplied material or about a blend.

Ipamorelin is a pentapeptide, Aib-His-D-2Nal-D-Phe-Lys-NH2, whose original characterisation in rat pituitary cells, rats and swine found GH release comparable to GHRP-6 with no rise in ACTH or cortisol beyond the GHRH-stimulated level, and an action at a GHRP-like receptor rather than the GHRH receptor. The two compounds therefore engage different receptors on the same cell type.

Unlike the other blends, the ratio here is not constant: TI10 is 5 mg of each, TI14 is 10 mg tesamorelin with 4 mg ipamorelin, and TI15 is 10 mg with 5 mg. No study of the fixed blend is cited. Supplied as lyophilised powder for in-vitro and preclinical research only.

Research class: Fixed two-compound research blend

Components: Tesamorelin + Ipamorelin

Vial strengths: 10 mg, 14 mg, 15 mg per vial, chosen from the pack-size menu

Research focus: Pituitary growth hormone release through the GHRH receptor and a ghrelin-type receptor

Evidence base: Randomised human trials of tesamorelin alone in HIV-related settings; animal and in-vitro data for ipamorelin; none on the blend

Proposed Mechanism

The blend has no combined mechanism. Tesamorelin is a GHRH-receptor agonist and ipamorelin a ghrelin-type receptor agonist, both acting on pituitary somatotrophs. Pairing them is a hypothesis about two receptors, not a demonstrated property of the vial.

Pathway Effect Why it matters GHRH receptor (tesamorelin) GHRH(1-44) analogue with an N-terminal modification Its trial results are the best-documented human data in this listing, and all concern tesamorelin alone Ghrelin-type receptor (ipamorelin) Releases GH through a GHRP-like receptor, not the GHRH receptor The second route the pair is chosen to engage IGF-I Raised 81% in the 26-week tesamorelin trial A downstream marker reported for tesamorelin alone No shared pharmacology Each component retains its own published pharmacology Interpret results per component, not for the pair

Deeper dive for scientific readers

The tesamorelin trials were done in particular patient populations with the approved medicine and say nothing about a laboratory blend, about ipamorelin, or about the other strengths here. The ratio also changes between TI10, TI14 and TI15, so no single composition can be assumed across the menu. When a design needs one compound varied against the other, use the stand-alone tesamorelin and ipamorelin products.

Common Questions People Are Asking

What strengths does the tesamorelin + ipamorelin blend come in?

Three, chosen from the pack-size menu: 10 mg per vial (5 mg tesamorelin + 5 mg ipamorelin, code TI10), 14 mg (10 + 4, TI14) and 15 mg (10 + 5, TI15). The ratio is not the same in each.

Is this the approved tesamorelin medicine?

No. Tesamorelin is the active ingredient of an approved prescription medicine for a specific condition, but the material supplied here is unapproved laboratory research material and is not that product.

Why are tesamorelin and ipamorelin paired?

They act on the same pituitary cell type through different receptors, tesamorelin at the GHRH receptor and ipamorelin at a ghrelin-type receptor. That is the rationale for studying them together. This page cites no study of the fixed blend.

Is there a Certificate of Analysis for this blend?

Not yet. No independent analytical report has been published for this material, so no purity figure is quoted. If one is published it will appear on this page and on our COA page.

Is there human data on this blend?

No study of the blend is cited. The human trials in the references are of tesamorelin alone in specific patient groups. This is laboratory research material, sold strictly for in-vitro and preclinical research and not for human or veterinary use.

Where can I buy Tesamorelin + Ipamorelin Blend?

Right here - Tesamorelin + Ipamorelin Blend is supplied directly by New-U Research Compounds on this page, as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.

How much does Tesamorelin + Ipamorelin Blend cost?

Tesamorelin + Ipamorelin Blend pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Shipping is free on orders over $350.

How do I buy Tesamorelin + Ipamorelin Blend?

Add the Tesamorelin + Ipamorelin Blend pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step.

What payment methods can I use to buy Tesamorelin + Ipamorelin Blend?

At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.

How fast is shipping, and do you ship worldwide?

Yes - we ship worldwide in discreet, unmarked, tracked packaging; lyophilised peptides are stable through the tracked transit window. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.

Is it legal to buy Tesamorelin + Ipamorelin Blend?

In the United States, Tesamorelin + Ipamorelin Blend is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Stability Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. Notes Laboratory research material. No amount, schedule or administration guidance is published or recommended on this page.

Evidence Tier

Overall: Tier 3: Limited / anecdotal

The blend has no evidence base of its own. The human trials cited concern tesamorelin alone in HIV-related settings; ipamorelin has animal and in-vitro pharmacology. No study of the two as a fixed combination is cited. The material is supplied as unapproved laboratory material, not as the approved tesamorelin medicine.

Tier 1 · Human clinical

A 26-week randomised placebo-controlled trial of tesamorelin in 412 people with HIV and abdominal fat accumulation

A 12-month randomised placebo-controlled trial of tesamorelin in 61 people with HIV and fatty liver disease

Tier 2 · Animal

Ipamorelin GH release and selectivity in rat pituitary cells, rats and swine

Databases & peer-reviewed sources

Last reviewed: 14 October 2026 · New-U Research Compounds

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007. · 2007 · PMID: 18057338 · DOI: 10.1056/NEJMoa072375

Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019. · 2019 · PMID: 31611038 · DOI: 10.1016/S2352-3018(19)30338-8

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. · 1998 · PMID: 9849822 · DOI: 10.1530/eje.0.1390552

PubMed: peer-reviewed literature on Tesamorelin + Ipamorelin Blend

ClinicalTrials.gov: registered studies on Tesamorelin + Ipamorelin Blend

Tesamorelin + Ipamorelin Blend: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

Tesamorelin plus ipamorelin in every vial, in three strengths

TI10 is 5 + 5 mg, TI14 is 10 + 4 mg, TI15 is 10 + 5 mg (10, 14 and 15 mg per vial)

Tesamorelin: GHRH(1-44) analogue with a trans-3-hexenoyl N-terminus, about 5,136 Da

Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys-NH2, about 712 Da

The ratio differs by strength

No study of the fixed blend is cited; human trials cited concern tesamorelin alone

No analytical report published yet; sold as a sealed 10-vial pack, one strength per pack

Specifications

Components Tesamorelin + Ipamorelin Vial TI10 Tesamorelin 5 mg + Ipamorelin 5 mg (10 mg per vial) Vial TI14 Tesamorelin 10 mg + Ipamorelin 4 mg (14 mg per vial) Vial TI15 Tesamorelin 10 mg + Ipamorelin 5 mg (15 mg per vial) Pack 10 vials, one strength per pack Analytical report None published yet Form Lyophilised powder Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light.

About the Tesamorelin + Ipamorelin Blend: Research Guide

Tesamorelin and ipamorelin are both studied for how they drive pituitary growth hormone release, one through the GHRH receptor and the other through a ghrelin-type receptor. A single vial removes a weighing and reconstitution step for studies that call for both, and three strengths let the tesamorelin and ipamorelin amounts follow the design.

Tesamorelin is also the active ingredient of an approved prescription medicine for a specific condition. The material supplied here is laboratory research material and is not that product; the trials in the references are published findings about tesamorelin in those patients and are not claims about this blend or about use in anyone.

New-U Research Compounds supplies this blend as laboratory research material only. No analytical report for it has been published yet, so no purity figure is quoted. Nothing on this page is medical advice.

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007.

Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019.

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998.

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Stacks

Stacks BPC-157 + TB-500 Blend BPC-157 and TB-500 in one vial at a fixed 1:1 ratio, in four strengths from 2 mg + 2 mg to 15 mg + 15 mg per vial: the two most-cited tissue-repair research peptides, pre-combined. BPC-157 + TB-500 Blend →

Stacks CJC-1295 (No DAC) + Ipamorelin Blend CJC-1295 (no DAC) and ipamorelin in one vial at a fixed 1:1 ratio, in two strengths: 5 mg + 5 mg and 10 mg + 10 mg per vial. A GHRH analogue paired with a selective ghrelin-receptor agonist. CJC-1295 (No DAC) + Ipamorelin Blend →

Stacks Semax + Selank Blend Semax and Selank in one vial at a fixed 1:1 ratio, in two strengths: 5 mg + 5 mg and 10 mg + 10 mg per vial. Two heptapeptides developed at the same Moscow institute. Semax + Selank Blend →

Stacks Glow Glow is a three-compound research blend combining GHK-Cu, BPC-157 and TB-500 in a single vial - the copper-binding tripeptide paired with the two most-studied tissue-repair peptides. Glow →

Stacks Klow Klow is a four-compound research blend - the Glow trio of GHK-Cu, BPC-157 and TB-500 with KPV added, pairing matrix and repair signalling with the alpha-MSH anti-inflammatory fragment. Klow →

Tesamorelin + Ipamorelin Blend vs related Stacks compounds

Compound Price Purity spec COA Tesamorelin + Ipamorelin Blend from $220 Not published On request BPC-157 + TB-500 Blend from $140 Not published On request CJC-1295 (No DAC) + Ipamorelin Blend from $180 Not published On request

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Tesamorelin + Ipamorelin Blend

Multi-Compound Blends research compounds

Tesamorelin + Ipamorelin Blend research guide

Research this compound

Research guide Tesamorelin + Ipamorelin Blend research guide The blend has no combined mechanism. Read the guide →

Part of the Growth hormone secretagogue research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research